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Abstract 
Introduction: In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering 
therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 
inhibitors (‘gliptins’). 
Areas covered: The cardiovascular safety trials for saxagliptin and alogliptin have recently been 
published and are the subject of this evaluation. 
Expert Opinion: The SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in 
Patients with Diabetes Mellitus -Thrombolysis in Myocardial Infarction (TIMI) 53 trial) and EXAMINE 
(Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) were both 
multicentre, randomised, double-blind, placebo-controlled, Phase IV clinical trials.  These trials 
showed that saxagliptin and alogliptin did not increase the primary endpoint, which was a composite 
of cardiovascular outcomes that did not include hospitalizations for heart failure.  However, 
saxagliptin significantly increased hospitalization for heart failure, which was a component of the 
secondary endpoint.  The effect of alogliptin on hospitalizations for heart failure has not been 
reported.  Neither agent improved cardiovascular outcomes.  Whilst there is no published evidence 
of improved outcomes with gliptins, it is unclear to us why these agents are so widely available for 
use.  We suggest that the use of gliptins be restricted to Phase IV clinical trials until such time as 
cardiovascular safety and benefits/superiority are clearly established. 
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1. Introduction 
In the United States, the prevalence of diabetes is about 8% (24 million people), and 90% of this is 
type 2, which has both lifestyle and genetic components [1].  Despite the treatments available for 
type 2 diabetes, about two thirds of the subjects die from heart disease or stroke, and almost all 
experience premature cardiovascular morbidity culminating in amputations and myocardial 
infarction with cardiac failure [1].   
In 1998, the UK prospective diabetes study (UKPDS 35) suggested a significant relationship between 
glycaemia and clinical complications with every 1% reduction in HbA1c being associated with a 21% 
reduction in the risk for any endpoint related to diabetes, 21% of deaths related to diabetes, 14% of 
myocardial infarction, and 37% for microvascular complications [2].  Higher HbA1c levels were also 
associated with increased risk of microvascular complications such as chronic kidney disease, end-
stage kidney disease and retinopathy, in the Atherosclerosis Risk in Communities Study [3].  
Consequently, from this time, HbA1c levels were often considered to be a surrogate marker for 
cardiovascular risk with high levels indicating high risk, and reductions in HbA1c reducing risk. 
However, in 2008, this straight forward relationship between HbA1c levels and cardiovascular risk 
was challenged by the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial 
[4].  ACCORD showed that the intensive lowering of HbA1c to 6.4% was associated with an increased 
risk of mortality, compared to standard therapy (HbA1c of 7.5%), without affecting major 
cardiovascular events [4].  Thus, HbA1c levels cannot always be considered a surrogate for 
cardiovascular risk or safety.  This led the Federal Drug Administration (FDA) in 2008 to require that 
all new glucose-lowering therapies should be required to show cardiovascular safety [5].  
Subsequently, the thiazolidinedione, rosiglitazone, was shown to lower HbA1c but to increase 
cardiovascular risk [6,7].  With the addition of these findings with rosiglitazone, the European 
Medicines Agency (EMA) concurred in 2010 that all new glucose-lowering therapies should be 
required to show cardiovascular safety [8]. The FDA Guidance for Industry suggests that the safety of 
new antidiabetic therapy can be evaluated either from integrated analysis of the Phase II and Phase 
III clinical trial or by additional Phase IV large safety trials [9]. 
The dipeptidyl peptidase (DPP)-4 inhibitors are relatively new group of medicines for the treatment 
of diabetes.  These agents inhibit the degradation of the incretin hormones, leading to the increased 
levels of these hormones.  These hormones stimulate insulin secretion, with the reduction of HbA1c 
levels in subjects with type 2 diabetes.  Sitagliptin was approved in 2006, subsequent to which 
vilagliptin, saxagliptin, alogliptin and linagliptin have been approved.  The first two cardiovascular 
risk Phase IV trials, performed under the requirements of the FDA and EMA, have recently been 
published.  The trial for saxagliptin is the Saxagliptin Assessment of Vascular Outcomes Recorded in 
Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial, and 
the trial for alogliptin is the Examination of Cardiovascular Outcomes with Alogliptin versus Standard 
of Care (EXAMINE).  We have evaluated the SAVOR-TIMI 53 and EXAMINE trials and can confirm that 
saxagliptin and alogliptin do not increase composite cardiovascular outcomes, which did not include 
hospitalizations for heart failure.  However, saxagliptin significantly increased hospitalization for 
heart failure, and alogliptin was not tested for its effects on hospitalizations for heart failure. 
2. Saxagliptin in SAVOR-TIMI 53 
2.1 Introduction 
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The Saxagliptin Registration Phase II and Phase III trials established that saxagliptin reduced HbA1c in 
type 2 diabetes, and were subsequently combined in a systematic analysis of the cardiovascular risk 
of saxagliptin [10].  This analysis, of 4607 subjects with type 2 diabetes, suggested that saxagliptin 
did not change cardiovascular events and death [10].  However, limitations included that review of 
cardiovascular events was not independent, the trials were limited to drug-naïve and monotherapy-
treated subjects, there were low event numbers, the subjects had a relatively short duration of 
diabetes, and participants were only monitored for a short time [10].  These limitations may explain 
in part how the increased cardiac failure with saxagliptin observed in SAVOR-TIMI 36 was 
overlooked. 
2.2 Methods and results 
The methods and results of the SAVOR-TIMI 53 trial [11] are summarised in this section.  SAVOR-
TIMI was a randomised, double-blind, placebo-controlled Phase IV trial performed in 26 countries.  
The trial was designed as a superiority trial of cardiovascular outcomes of saxagliptin versus placebo, 
with testing for non-inferiority, prior to testing for superiority.   
To be enrolled, subjects with type 2 diabetes had to have an HbA1c of 6.5-12%, and either a history 
of established cardiovascular disease or multiple risk factors for vascular disease.  Subjects were not 
enrolled if they had received incretin-based therapy in the previous 6 months or had kidney 
dysfunction (renal transplantation, end-stage renal failure, or serum creatinine > 530 µmol/l).   
The 16,492 subjects enrolled had a mean age of ~65 years, a mean HbA1c of 8.0%, and duration of 
diabetes ~10 years, and about two-thirds were male and 22% were Hispanic, and 75% were White.  
Most of the enrolled subjects had hypertension (~81%), established atherosclerotic disease (~79%) 
and dyslipidemia (~71%), and some had prior coronary revascularization (~43%), prior myocardial 
infarction (~38%) and/or prior heart failure (~13%).   Subjects were randomised to saxagliptin (5 mg), 
which was lowered to 2.5 mg if renal impairment developed, or placebo, and the median follow-up 
was 2.9 years. 
At baseline, diabetes medications were similar in both groups with ~70% of subjects taking 
metformin, ~40% taking sulphonylureas, and ~41% insulin.  The use of these medications did not 
change throughout the study in the saxagliptin group, but in the placebo group, insulin use had 
increased to ~46% by year 2.  The HbA1c levels were significantly lower in the saxagliptin group than 
placebo group after 1 year (7.6% vs 7.9%), 2 years (7.5% vs 7.8%) and at the end of study (7.7% vs 
7.9%).   
The primary efficacy and safety end point was a composite of cardiovascular death, nonfatal 
myocardial infarction or nonfatal ischemic stroke, and this occurred in 613 (7.3%) subjects in the 
saxagliptin group, compared in 609 (7.2%) in the placebo group.  The secondary end points included 
the primary endpoint plus hospitalization for heart failure, coronary revascularization, or unstable 
angina, which occurred in 1059 subjects (12.8%) with saxagliptin and 1034 subjects (12.4%) with 
placebo.  Analysis of the individual cardiovascular items showed they were similar in both groups, 
except for hospitalization for heart failure which was 27% higher in the saxagliptin group (289 
subjects, 3.5%) than the placebo group (228 subjects, 2.8%, P = 0.007).   
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Kidney function was measured as a combination of doubling of creatinine level, initiation of dialysis, 
renal transplantation, or creatinine >6.0 mg/dl, and this was similar in both the both the saxagliptin 
group (194 subjects, 2.2%) and placebo group (178 subjects, 2.0%).  At the start of the study, the 
albumin-to-creatinine ratio was 1.8 in the saxagliptin and 1.9 in the placebo group, and at the end of 
the study, less subjects taking saxagliptin had a worsening of this ratio (833, 13.3%) than in the 
placebo group (969, 15.9%). 
Hypoglycaemia occurred more often in the saxagliptin group (1264 subjects, 15.3%) than the 
placebo group (1104 subjects, 13.4%, P < 0.001).  Major hypoglycaemia requiring a third party in 
intervene actively was marginally more common in the saxagliptin (177 subjects, 2.1%) than the 
placebo group (140 subjects, 1.7%, P = 0.047).  Rates of pancreatitis and other safety end points (e.g. 
cancer, liver abnormalities, blood cell dysfunction, infections) were similar in both groups. 
2.3 Discussion 
The authors concluded, that with regard to the primary composite endpoint of cardiovascular death, 
myocardial infarction or ischemic stroke, saxagliptin was not inferior to placebo, but it also did not 
provide any cardioprotective benefit [11].  In the discussion, the authors gave three possible reasons 
for the failure of the study to show any cardiovascular benefit with saxagliptin: firstly, the study may 
have been too short to show benefit; secondly, the difference in HbA1c was too small between the 
groups because to the increased use of insulin in the placebo group; and thirdly, the number of 
endpoints was substantially reduced by the frequent use of statins, anti-platelet therapy, and blood-
pressure-lowering agents [11]. 
The authors suggested that the increased risk of hospitalisation with heart failure, in the saxagliptin 
group, may have been a false positive result [11].  However, they do concede that this finding 
requires further investigation [11]. 
3. Alogliptin in EXAMINE 
3.1 Introduction 
The developmental Phase II and III trials of alogliptin established that alogliptin lowered HbA1c in 
subjects with type 2 diabetes, and have been pooled to assess cardiovascular safety [12].  This 
pooling had 4168 subjects with type 2 diabetes that had been treated with alogliptin, and 2023 
treated with placebo, and showed that alogliptin had no effect on the composite of cardiovascular 
death, non-fatal myocardial infarction and non-fatal stroke [12].  However, this pooling had several 
limitations: the studies were not designed to measure cardiovascular safety, the duration of the 
clinical trials was short, the population had only moderate cardiovascular risk and the number of 
cardiovascular endpoints was relatively low [12].  Subsequently, the cardiovascular risk of alogliptin 
has been determined in EXAMINE, which did not have these limitations. 
3.2 Methods and results 
The methods and results the EXAMINE trial are summarised in this section [13].  EXAMINE was a 
non-inferiority trial of alogliptin and placebo, and showed that alogliptin has no effect on a 
composite endpoint of cardiovascular safety.   
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EXAMINE was a randomised, double-blind, placebo-controlled trial performed in 49 countries.  To be 
enrolled, subjects with type 2 diabetes had to have an HbA1c of 6.5-11% or, if taking insulin, 7-11%, 
and have had an acute coronary syndrome (e.g. acute myocardial infarction, unstable angina 
requiring hospitalization) within the last 15 to 90 days.  Subjects were not enrolled if they had 
unstable cardiovascular disorders such as class IV heart failure, or had had undergone dialysis within 
14 days before screening. 
The 5380 subjects that participated in EXAMINE had a mean age of 61 years, a mean HbA1c of 8.0%, 
and a duration of diabetes of 7 years, and most were male (~68%) and white (~73%) or Asian (~20%).  
Most of the participants had had a myocardial infarction (~88%) and/or a percutaneous coronary 
intervention (~63%) and/or coronary-artery intervention (~13%), and most were hypertensive 
(~83%), and some had congestive heart failure (~28%), peripheral arterial disease (~10%), or a 
previous stroke (~7%).  Subjects were allocated to placebo or alogliptin, and the dose of alogliptin 
was dependent on kidney function with a dose of 25 mg in subjects with a glomerular filtration rate 
(GFR) of 60 ml/min/173 m2, 12.5 mg in subjects with GFR of 30 to < 60 ml/min/173 m2, or 6.25 mg in 
subjects with GFR < 30 ml/min/173 m2, and the median follow-up was ~18 months. 
At the start of the study, diabetes medications were similar in both groups, with ~66% of subjects 
taking metformin, ~46% taking sulphonylureas, and ~30% insulin.  The HbA1c levels were lowered in 
the alogliptin group, compared to the placebo group, and the mean change from 8.0% was in the 
range of 0.3-0.6%. 
The primary end points was a composite of death from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke, and this was similar in both groups; occurring in 305 (11.3%) in the 
alogliptin group, compared to 316 (11.8%) in the placebo group.  There was also no difference in the 
components of the primary end points between groups.  In addition, the secondary end point 
included urgent revascularization due to unstable angina, and this was not different between 
groups.  Alogliptin did not alter the glomerular filtration rate. 
The rates of serious hypoglycemia (placebo, 0.6%; alogliptin, 0.7%) and any hypoglycemia (placebo, 
6.5%; alogliptin, 6.7%) were similar in both groups.  Rates of pancreatitis and other safety endpoint 
(e.g. cancer, angioedema, liver enzyme abnormalities and kidney function) were not different 
between groups. 
3.3 Discussion 
As EXAMINE did not show cardiovascular risk or benefit, but the median duration was only 18 
months, the authors could not rule out longer-term risks or benefits with alogliptin [13]. 
4. Expert opinion 
4.1 Populations 
The populations of both SAVOR-TIMI 53 and EXAMINE were predominantly white, and thus the 
findings of these studies predominantly apply to whites taking saxagliptin or alogliptin.  However, 
some other populations with type 2 diabetes have a higher incidence and more cardiovascular 
related disease e.g. Hispanics and blacks.  SAVOR-TIMI 53 has a significant population of Hispanics 
(22%), but EXAMINE does not.  The findings for sub-population of Hispanics in SAVOR-TIMI have not 
reported, and should be.  Neither SAVOR-TIMI 53 nor EXAMINE have a significant sub-population of 
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blacks.  Thus, the cardiovascular safety and benefits of gliptins need to be studied in populations, 
other than whites, including Hispanics and blacks. 
4.2 Change in diabetic medications/HbA1c during study 
In SAVOR-TIMI 53, the use of anti-diabetes medicines was matched at baseline [11].  However, there 
was an increased use of insulin in the placebo, but not the saxagliptin group, during the study, and 
thus the anti-diabetes medications were no longer matched between the groups [11].  The increased 
use of insulin in the placebo group was likely to diminish the difference in HbA1c levels between the 
placebo group and the saxagliptin group, such that it was small (0.2-0.3%).  In EXAMINE, the use of 
anti-diabetes medicines was also matched at baseline [12], but it was not reported whether this 
changed during the study.  Thus, we do not know whether the use of anti-diabetes medicines 
remained matched or not during the study.   
EXAMINE also does not report HbA1c values for the placebo and alogliptin groups, but reports mean 
changes in HbA1c from 8.0%, which were in the range 0.3-0.5%, which equates to a reduction in 
HbA1c of 0.2-0.4%, which is similar to the reduction with saxagliptin in SAVOR-TIMI 51.  It would be 
easier to compare the studies, and to compare with other studies, if EXAMINE had given the 
absolute values for HbA1c. 
In UKPDS 35, reductions in cardiovascular outcomes of 14-37% were associated with a 1% reduction 
in HbA1c in subjects with type 2 diabetes [2].  It is possible that there were no effects on 
cardiovascular outcomes (safety or beneficial) for saxagliptin in SAVOR-TIMI 53 or for alogliptin in 
EXAMINE because the reductions in HbA1c of 0.2-0.4% were too small to significantly affect clinical 
outcomes.   
4.3 Hospitalizations for heart failure and ongoing trials with gliptins 
To date, there is only one meta-analysis that includes hospitalizations for heart failure in the analysis 
of gliptins as a group, and this was a presentation to the Australasian Society of Experimental and 
Clinical Pharmacologists and Toxicologists, and reported that dipeptidyl peptidase-4 inhibitors had 
no effect on all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, but 
significantly increased hospitalization for heart failure [14].   
Despite only enrolling 13% of subjects with heart failure, SAVOR-TIMI 53 shows that saxagliptin 
increased hospitalizations for heart failure [11].  Subjects with class IV heart failure were not 
enrolled in EXAMINE, but EXAMINE did enrol a higher percentage of subjects with heart failure (28%) 
than SAVOR-TIMI 53.  However, hospitalization for heart failure was not an endpoint in EXAMINE, 
and [13], and thus we do not whether alogliptin has an effect on hospitalizations for heart failure.  
Despite sitagliptin being approved in 2008, no Phase III/IV cardiovascular safety or benefit outcome 
trials have been reported to date.  However, the Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin (TECOS) is in progress, and will report on cardiovascular safety [15].  Meta-analysis of the 
Phase III programme, suggested that linagliptin had no effect on cardiovascular outcomes [16], and it 
is being compared to glimepiride in a cardiovascular outcomes trial; Cardiovascular Outcome Study 
of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA), but CAROLINA will not 
be completed until 2018 [17].  Thus, neither TECOS nor CAROLINA has hospitalization for heart 
failure as an endpoint.  To our knowledge, there is no ongoing cardiovascular risk trial with 
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vildagliptin.   Thus, even when all the trials are completed, we may not be clear as to whether 
sitagliptin, linagliptin or vildagliptin increase heart failure.  Given the finding that saxagliptin 
increased hospitalization for heart failure in SAVOR-TIMI 53, this should be an essential study 
endpoint for cardiovascular safety trials with all gliptins.  Thus, hospitalizations for heart failure 
should be added as an endpoint to all ongoing cardiovascular safety trials with gliptins, if possible.  If 
this is not possible, new clinical trials may have to be set up to evaluate the effects of gliptins on 
hospitalizations for heart failure.  In any new studies of the effect of gliptins on cardiovascular safety, 
hospitalizations for heart failure need to be an endpoint.  Any further meta-analyses of gliptins as a 
group, or individually, should also consider hospitalizations for heart failure. 
4.4 Cardiovascular benefits 
Microvascular disease was not evaluated in either SAVOR-TIMI 53 or EXAMINE for unclear reasons, 
perhaps lack of power, despite the obvious clinical importance of retinopathy, neuropathy and 
nephropathy.  In SAVOR-TIMI 53, subjects with kidney dysfunction were excluded, and kidney 
function was measured as a surrogate of the combination of doubling of creatinine level, initiation of 
dialysis, renal transplantation, or creatinine >6.0 mg/dl, which was not altered by saxagliptin.   These 
kidney function parameters are not given for alogliptin in EXAMINE.  However, it should be noted 
that in both SAVOR-TIMI 53 and EXAMINE, about 80% of all subjects were taking a blocker of the 
renin-angiotensin system throughout, and these will have offered nephroprotection.   Nevertheless, 
in our opinion, improvements in microvascular disease probably should be demonstrated 
unequivocally with each class of diabetic pharmacotherapy.  Thus, one of the major limitations to 
the studies to date with the saxagliptin and alogliptin (and the other gliptins) is that no clinically 
beneficial outcomes (e.g. on cardiovascular mortality and morbidity) have emerged in published in 
individual studies or meta-analysis of individual studies [18].  Thus, meta-analysis of 12 trials with 
events for saxagliptin and 4 trials with alogliptin, did not show a significant effect on cardiovascular 
mortality and morbidity [18]. 
4.5 Conclusions 
The cardiovascular safety of gliptins in type 2 diabetes mellitus is unclear in the light of a significant 
increase in hospitalizations for heart failure with saxagliptin increased the rate [11].  The gliptins 
have also not been demonstrated to lower cardiovascular events or microvascular disease.  Whilst 
there is no published evidence of improved outcomes with gliptins, it is unclear why these agents 
are so widely available and utilised.  We suggest that the use of gliptins be restricted to Phase IV 
clinical trials until such time as cardiovascular safety and benefits/superiority are clearly established. 
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